Pliant Therapeutics Receives Fast Track Designation From FDA For PLN-101095 In Combination With Pembrolizumab For Potential Treatment Of Solid Tumors

뉴스 본문을 불러오고 있어요.

Pliant Therapeutics Receives Fast Track Designation From FDA For PLN-101095 In Combination With Pembrolizumab For Potential Treatment Of Solid Tumors | 웨이프 WAPE

Pliant Therapeutics Receives Fast Track Designation From FDA For PLN-101095 In Combination With Pembrolizumab For Potential Treatment Of Solid Tumors

기사 요약

관련 종목

댓글 —